Bone Morphogenetic Protein 6 Inhibits the Immunomodulatory Property of BMMSCs via Id1 in Sjögren’s Syndrome

Figure 1

BMP6 was overexpressed in BMMSCs of SS patients and NOD mice and regulated BMMSCs differentiation. Real-time RT-PCR results indicated that the mRNA level of BMP6 is about five times higher in SS patient BMMSCs (a) and eight times higher in NOD BMMSCs (b) than in normal BMMSCs (, ). (c) ELISA showed that the BMP6 protein level is higher in the supernatant of NOD BMMSCs culture medium compared with BALB/c (). (d, e) BMP6-treated BMMSCs showed a significant increase in ALP activity compared to untreated controls (). Real-time RT-PCR analysis demonstrated elevated expression of BGLAP mRNA (h) and ALP mRNA (i) in BMP6-treated cells (, ). (f, g) Oil Red O staining showed that BMP6 has no effect on cellular lipid accumulation in BMMSCs. Real-time RT-PCR results revealed that BMP6 do not increase the expression of PPARγ mRNA (j) and FABP4 mRNA (k). N.S.: no significant difference.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)